SUNITINIB FORMULATIONS AND METHODS FOR USE THEREOF IN TREATMENT OF GLAUCOMA

Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more sustained controlled release of sunitinib or other inhibitors of JNK signaling, which bind to DLK. Increased loading is achieved using an al...

Full description

Saved in:
Bibliographic Details
Main Authors WELSBIE, DEREK, STUART, HANES, JUSTIN, YANG, ZHIYONG, ZACK, DONALD, JEFFREY, BERLINICKE, CYNTHIA, ANN, FU, JIE
Format Patent
LanguageEnglish
French
Published 23.06.2016
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more sustained controlled release of sunitinib or other inhibitors of JNK signaling, which bind to DLK. Increased loading is achieved using an alkaline solvent system. The pharmaceutical compositions can be administered to treat or reduce neuronal death due to elevated intraocular pressure. Upon administration, the sunitinib or other inhibitor is released over an extended period of time at concentrations which are high enough to produce therapeutic benefit, but low enough to avoid unacceptable levels of cytotoxicity, and which provide much longer release than inhibitor without conjugate. L'invention concerne des procédés destinés à augmenter l'encapsulation ou l'incorporation du sunitinib dans des matrices polymères. Les formulations ainsi obtenues assurent une libération contrôlée plus longue du sunitinib ou d'autres inhibiteurs de la signalisation de la JNK, qui se lient à la DLK. L'augmentation de la charge est obtenue au moyen d'un système de solvant alcalin. Les compositions pharmaceutiques peuvent être administrées pour traiter ou réduire la mort neuronale liée à une pression intra-oculaire élevée. Lors de son administration, le sunitinib ou un autre inhibiteur est libéré sur une période de temps longue et à des concentrations qui sont suffisamment élevées pour produire un effet thérapeutique, mais suffisamment basses pour éviter des niveaux inacceptables de cytotoxicité, et qui apportent une libération bien plus longue qu'un inhibiteur non conjugué.
AbstractList Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more sustained controlled release of sunitinib or other inhibitors of JNK signaling, which bind to DLK. Increased loading is achieved using an alkaline solvent system. The pharmaceutical compositions can be administered to treat or reduce neuronal death due to elevated intraocular pressure. Upon administration, the sunitinib or other inhibitor is released over an extended period of time at concentrations which are high enough to produce therapeutic benefit, but low enough to avoid unacceptable levels of cytotoxicity, and which provide much longer release than inhibitor without conjugate. L'invention concerne des procédés destinés à augmenter l'encapsulation ou l'incorporation du sunitinib dans des matrices polymères. Les formulations ainsi obtenues assurent une libération contrôlée plus longue du sunitinib ou d'autres inhibiteurs de la signalisation de la JNK, qui se lient à la DLK. L'augmentation de la charge est obtenue au moyen d'un système de solvant alcalin. Les compositions pharmaceutiques peuvent être administrées pour traiter ou réduire la mort neuronale liée à une pression intra-oculaire élevée. Lors de son administration, le sunitinib ou un autre inhibiteur est libéré sur une période de temps longue et à des concentrations qui sont suffisamment élevées pour produire un effet thérapeutique, mais suffisamment basses pour éviter des niveaux inacceptables de cytotoxicité, et qui apportent une libération bien plus longue qu'un inhibiteur non conjugué.
Author FU, JIE
ZACK, DONALD, JEFFREY
BERLINICKE, CYNTHIA, ANN
YANG, ZHIYONG
HANES, JUSTIN
WELSBIE, DEREK, STUART
Author_xml – fullname: WELSBIE, DEREK, STUART
– fullname: HANES, JUSTIN
– fullname: YANG, ZHIYONG
– fullname: ZACK, DONALD, JEFFREY
– fullname: BERLINICKE, CYNTHIA, ANN
– fullname: FU, JIE
BookMark eNqNiksKwjAUALPQhb87PHAtJBaK29i-mGCTQPKCy1IkriQt1PujggdwNQwza7YoY8krdo3JGTLOnEH5YFMnyXgXQboWLJL2bfwGSBGBNAb0CowDCijJoiP4-KWTqfFWbtnyMTznvPtxw_YKqdGHPI19nqfhnkt-9Td_5KIWnFcnLkX13_UGgvUwUw
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate FORMULATIONS DE SUNITINIB ET MÉTHODES D'UTILISATION DE CES DERNIÈRES DANS LE TRAITEMENT DU GLAUCOME
ExternalDocumentID WO2016100380A1
GroupedDBID EVB
ID FETCH-epo_espacenet_WO2016100380A13
IEDL.DBID EVB
IngestDate Fri Oct 25 05:42:50 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_WO2016100380A13
Notes Application Number: WO2015US65878
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160623&DB=EPODOC&CC=WO&NR=2016100380A1
ParticipantIDs epo_espacenet_WO2016100380A1
PublicationCentury 2000
PublicationDate 20160623
PublicationDateYYYYMMDD 2016-06-23
PublicationDate_xml – month: 06
  year: 2016
  text: 20160623
  day: 23
PublicationDecade 2010
PublicationYear 2016
RelatedCompanies THE JOHNS HOPKINS UNIVERSITY
RelatedCompanies_xml – name: THE JOHNS HOPKINS UNIVERSITY
Score 3.0366
Snippet Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title SUNITINIB FORMULATIONS AND METHODS FOR USE THEREOF IN TREATMENT OF GLAUCOMA
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160623&DB=EPODOC&locale=&CC=WO&NR=2016100380A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp-LHlIDSt-Lapq0-DOn6YadrO7ZU9zaStgNBuuEq_vte46Z72lsuB0dycLn7JXcXgFtqaRzdWIYgR-gqpdRUBbeFapmF6GRZZ6YJ2e0ztsKUPk_MSQM-1rUwsk_ot2yOiBaVob1X8rxe_F9ieTK3cnkn3nFq_hiwrqes0LGG4bhuKF6v6w8TL3EV10XcpsQjydPqZ7COg1hpBwNpW8K2115dl7LYdCrBIewOUV5ZHUGjKFuw767_XmvBXrR68sbhyvqWx_AyRrTG-nG_RxC7RengtwaYOLFHIp-FiTeuGSQd-4SF_shPAtKPCRv5Dqt79hOknwZO6iaRcwI3gc_cUMVVTf-UMH1LNrdgnEKznJfFGRBNzAwM47jF7ZzmGb1_KLhZ6LNc5zbnmnUO7W2SLrazL-GgJuvkKN1oQ7P6_Cqu0A1X4lpq7wdOvYSk
link.rule.ids 230,309,783,888,25577,76883
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8JAEJ4QNOJNUeMDdRNNb430CR6IKX3YSh8EtsqN7JaSmJhCpMa_73QF5cRtdyeZ7E4yO_PtPBbgXjcVhmYsQ5DDVVnXdUPmrMNl08h5O8vac4WLbp-x6af6y8SY1OBjUwsj-oR-i-aIqFEZ6nsp7uvl_yOWI3IrVw_8HZcWTx7tOdIaHSvojqua5PR77jBxEluybcRtUjwSNKUKg7UtxEp76GR3BVh67Vd1Kctto-Idwf4Q-RXlMdTyogkNe_P3WhMOonXIG4dr7VudwGCMaI0GcdAniN2iNPytASZW7JDIpX7ijCsCSccuob47chOPBDGhI9eiVc9-gvPn0ErtJLJO4c5zqe3LuKvpnxCmb8n2EbQzqBeLIj8HovC5hm4cM1lnps8yvfuYMyNX5zOVdRhTzAto7eJ0uZt8Cw2fRuE0DOLBFRxWpCpRStVaUC8_v_JrNMklvxGS_AGvYYeU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=SUNITINIB+FORMULATIONS+AND+METHODS+FOR+USE+THEREOF+IN+TREATMENT+OF+GLAUCOMA&rft.inventor=WELSBIE%2C+DEREK%2C+STUART&rft.inventor=HANES%2C+JUSTIN&rft.inventor=YANG%2C+ZHIYONG&rft.inventor=ZACK%2C+DONALD%2C+JEFFREY&rft.inventor=BERLINICKE%2C+CYNTHIA%2C+ANN&rft.inventor=FU%2C+JIE&rft.date=2016-06-23&rft.externalDBID=A1&rft.externalDocID=WO2016100380A1